The Food and Drug Administration will hold a public meeting on potential regulatory pathways for cannabis-containing and cannabis-derived products, on May 31, with additional opportunities for public comment. The agency will also create a working group to explore regulatory pathways for CBD-containing dietary supplements and conventional foods.
The move follows the passing of the Agriculture Improvement Act of 2018, in December, which removed hemp from the Controlled Substances Act. However, FDA retained the right to regulate products containing cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic Act, particularly food items.
In addition, the agency will update its webpage with answers to frequently asked questions on this topic to help members of the public understand how FDA’s requirements apply to cannabis products. It will also begin issuing warning letters to companies marketing CBD products with “egregious and unfounded claims that are aimed at vulnerable populations.”